Experiences with

Idarucizumab

Last month, the FDA gave full approval to idarucizumab (Praxbind, Boehringer Ingelheim) to reverse the anticoagulant effect of dabigatran (Pradaxa, Boehringer Ingelheim), a direct thrombin inhibitor, in the event of urgent surgery or life-threatening or uncontrolled bleeding."

Pradaxa has a special FDA approved drug Praxbind (Idarucizumab) but the FDA refused to approve the reversal drug AndexXA designed for the 3 Factor Xa drugs. Platelets are not the only concern regarding potential bleeding events as there are many clotting factors to consider as well.

Idarucizumab (Praxbind) is a monoclonal antibody that reverses the anticoagulant effect of dabigatran (Pradaxa) in patients who require emergency surgery or have life-threatening bleeding. This was news today in Oz. 

The US Food and Drug Administration (FDA) has granted accelerated approval to Praxbind (idarucizumab, Boehringer Ingelheim) to rapidly reverse the blood-thinning effects of the anticoagulant Pradaxa (dabigatran, Boehringer Ingelheim).